
Drug survival (all causes of treatment stop)



- Adalimumab
- Etanercept
- ▲ Infliximab
- Ustekinumab
- Secukinumab
- + Overall

Fig. S1. Hazard ratios of treatment stop due to all causes for adalimumab, etanercept, infliximab, ustekinumab, secukinumab, and all treatments combined, for the different response groups compared with Psoriasis Area and Severity Index (PASI)=0.